An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs RG 101 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Regulus Therapeutics
- 10 Oct 2017 Status changed from recruiting to completed.
- 08 Sep 2017 This study has been completed in Hungary as per European Clinical Trials Database.
- 12 Jun 2017 According to a Regulus Therapeutics media release, Regulus Therapeutics announced today that it plans to discontinue clinical development of RG-101 upon completion of the one remaining clinical study, which is expected to occur in July 2017.